"The FDA approval won't be material in terms of revenue, but it will be in terms of clinician interest, research funding interest and attention from US investors"
FYI on valuations.
Therasphere - the Sitrex equivalent now part of Boston Scientific - got to significant revenue may be even up to $US100m under an HDE for primary liver cancer before it got its PMA. It was a long haul to get there.
Ann: Patient treated in Spain proceeds to successful resection, page-13
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.01 |
Change
-0.025(2.43%) |
Mkt cap ! $14.29M | |||
| Open | High | Low | Value | Volume |
| $1.04 | $1.05 | $1.00 | $41.05K | 40.86K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $1.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.05 | 1249 | 1 |
View Market Depth
| Last trade - 15.47pm 20/06/2025 (20 minute delay) ? |
| OSL (ASX) Chart |